VGX-150 (Melanoma)
|
Melanoma:
Skin Cancer Facts |
| |
 |
Skin
cancer (both non-melanoma and melanoma skin cancer) is the
most common of all cancers accounting for more than 50% of
all malignancies. |
| |
|
Melanoma is responsible
for about 80% of all mortality due to skin. |
| |
|
The number of new
melanoma cases diagnosed in the United States is increasing.
About 8,000 people in the US died of melanomas during 2004.
|
| |
|
Since 1973, the
mortality rate for melanoma has increased by 50% |
| |
|
Median survival
in patients with metastatic melanoma ranges from 6 to 10 months
with few long-term survivors. |
VGX-150
is the DNA delivered form of Vpr. VGX has completed
GMP manufacturing of the product for Phase I clinical studies.
The pre-clinical animal toxicology studies are underway.
Pre-clinical efficacy studies have shown that direct injection
of VGX-150 in mouse models of melanoma leads to eradication
of tumors (Molecular Therapy, 2006). |
Direct Injection of VGX-150 into
Melanoma Eradicates Tumors In Mice |
|
